Fairness opinions › Acquirers
Abbott: healthcare acquisitions with fairness opinions
2 public-company targets, 2023-2025, $22B combined enterprise value. The multiples Abbott paid and the banker analyses behind each target board's recommendation.
Deals
2
Median EV / EBITDA paid
44.2x
Median EV / revenue paid
4.87x
| Announced | Target | Acquirer | Segment | EV | EV/EBITDA | EV/Rev | DCF rate | Fairness opinion |
|---|---|---|---|---|---|---|---|---|
| 2025-11-19 | Exact Sciences | Abbott | Diagnostics / Life Sciences | $21B | 44.2x | 6.41x | 10.5%–12.5% | Centerview Partners |
| 2023-02-08 | Cardiovascular Systems | Abbott | Medical Devices and Supplies | $850M | — | 3.32x | 10.5%–12.5% | J.P. Morgan |